Sign in
Taking people in South KoreaPhase 4

Compares enavogliflozin with dapagliflozin or empagliflozin for heart and kidney outcomes

Compares enavogliflozin with other diabetes drugs in adults with type 2 diabetes and heart risk.

Key facts

Who runs it
Yonsei University
Where
Seoul, South KoreaSee the site
Trial code
Registry title
A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients
Status
Recruiting
Phase
Phase 4
People taking part
2,862 people, planned
Started
22 Jan 2024
Expected to end
31 Dec 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Enavogliflozin
  • Dapagliflozin or Empagliflozin
Record updated
15 October 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who are on, or need, enavogliflozin, dapagliflozin or empagliflozin. It compares enavogliflozin with the other two drugs for heart and kidney outcomes.

Age
19 years and older
Sex
Men and women can join.
Disease stage
Type 2 diabetes. The summary says people with a history of, or at risk for, cardiovascular disease.
Earlier treatment
People are on treatment with, or need treatment with, enavogliflozin, dapagliflozin or empagliflozin within the label and reimbursement criteria.

Main reasons for not taking part

  • Types of diabetes other than type 2 diabetes
  • Moderate to severe liver impairment
  • Kidney function eGFR <60 mL/min/1.73 m2, end stage renal disease, or dialysis
  • Major comorbidities
  • Allergy to enavogliflozin, dapagliflozin or empagliflozin, or pregnancy or breastfeeding

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Male and female adults aged 19 years and older at screening
  • Subjects diagnosed with T2D at screening
  • Subjects on treatment with or requiring treatment with enavogliflozin, dapagliflozin, or empagliflozin within the scope of label and reimbursement criteria

Who cannot take part

  • Subjects with different types of diabetes mellitus other than T2D
  • Subjects with moderate to severe hepatic impairment
  • Subjects with a history of hypersensitivity to enavogliflozin, dapagliflozin, or empagliflozin and any of its components
  • Subjects with contraindications to SGLT-2 inhibitors, i.e., kidney function disorders with estimated glomerular filtration (eGFR) <60 mL/min/1.73 m2, end stage renal disease (ESRD), or on dialysis
  • Subjects with major comorbidities
  • Pregnant or breastfeeding women

Where in South Korea

  • Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of KoreaSeoul, South KoreaContact: Bong Soo Cha, MD, PhDTaking people

About the trial

What the trial wants to find out

The novel sodium-glucose cotransporter-2 (SGLT2) inhibitor, enavogliflozin, effectively reduces glycated hemoglobin (HbA1c) levels and body weight without increasing the risk of serious adverse events. However, its long-term clinical benefits concerning cardiovascular and renal outcomes have yet to be thoroughly studied. This study is an investigator-initiated, multicenter, randomized, pragmatic, open-label, active-controlled, non-inferiority trial. Eligible participants are adults aged 19 or older with type 2 diabetes who have a history of, or are at risk for, cardiovascular disease. A total of 2,862 participants will be randomly assigned to receive either enavogliflozin or other SGLT2 inhibitors with proven cardiorenal benefits, such as dapagliflozin or empagliflozin. The primary endpoint is the time to the first occurrence of a composite of major adverse cardiovascular and renal events. This trial aims to determine whether enavogliflozin is non-inferior to dapagliflozin or empagliflozin in terms of cardiorenal outcomes in patients with type 2 diabetes and cardiovascular risk factors. It will also clarify role of enavogliflozin in preventing vascular complications in this patient population.

The 2 groups in the trial

  • Enavogliflozin GroupTreatment being tested

    Subjects will take Enavogliflozin according to the investigator's judgment.

    Treatment: Enavogliflozin

  • Dapagliflozin, Empagliflozin GroupExisting treatment, for comparison

    Subjects will take Dapagliflozin or Empagliflozin according to the investigator's judgment.

    Treatment: Dapagliflozin or Empagliflozin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Open, Registry-based Randomized, Controlled, Investigator Initiated Trial of Enavogliflozin(ENVlo) to EvaLuate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients (ENVELOP Study)
Plain-language title
Compares enavogliflozin with dapagliflozin or empagliflozin for heart and kidney outcomesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 October 2024